Poster 38

[P-38-03] Enriching global perspectives through a regional lens: Recog-nition, Assessment, and Management of Tardive Dyskinesia in Southeast Asia

*KOK YOON CHEE¹, Roongroj Bhidayasiri², Jin Kiat Ang³, Chun Man, Roger Ho^4,5, Ahmad Shahir Mawardi⁶, Adhi Wibowo Nurhidayat⁷, Pongsatorn Paholpak⁸, Pornjira Pariwatcharakul⁹, Thitima Sanguanvichaikul¹⁰, Eng Khean Ung¹¹, Natalia Dewi Wardani¹², Kah Loke, Brian Yeo¹³ (1.DEPARTMENT OF PSYCHIATRY AND MENTAL HEALTH, KUALA LUMPUR HOSPITAL, MALAYSIA(Malaysia), 2.Chulalongkorn Centre of Excellence for Parkinson’s Disease & Related Disorders (ChulaPD), Chulalongkorn University, Bangkok(Thailand), 3.Department of Psychiatry, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor(Malaysia), 4.Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore(Singapore), 5.Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay(Hong Kong), 6.Department of Neurology, Hospital Kuala Lumpur, Kuala Lumpur(Malaysia), 7.Department of Psychiatry, Faculty of Medicine, UIN Syarif Hidayatullah Jakarta, South Tangerang(Indonesia), 8.Department of Psychiatry, Khon Kaen University, Khon Kaen(Thailand), 9.Department of Psychiatry, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok(Thailand), 10.Department of Psychiatry, Somdet Chaopraya Institute of Psychiatry(Thailand), 11.Adam Road Medical Centre, Singapore(Singapore), 12.Department of Psychiatry, Diponegoro University, Central Java(Indonesia), 13.Mount Elizabeth Medical Centre, Singapore(Singapore))

Keywords:

Tardive Dyskinesia,Tardive Syndrome,Southeast Asian Consensus

Tardive dyskinesia (TD), a movement disorder induced by dopamine receptor blocking agents (DRBAs), is not well recognized by most clinicians in Southeast Asia (SEA). Thus, guidance on assessment and management of TD is warranted. This consensus study aimed to provide recommendations on the assessment and management of TD in SEA. Eleven experts from the fields of neurology, neuropsychiatry, and psychiatry from Southeast Asian countries participated in the consensus development via the Modified RAND-UCLA Appropriateness Method, consisting of a review of literature, drafting clinical scenarios with ratings (Likert Scale: 1-9), followed by a face-to-face meeting that led to the recommendations. The expert panel recommended that patients taking DRBAs should be screened for TD every 6 months (Median [Mdn]: 9; Interquartile Range [IQR]: 8,9), regardless of the risk (Mdn: 8; IQR: 9,9). In cases where face-to-face physical con-sultation were not feasible, the panel agreed that TD could also be diagnosed (Mdn: 8; IQR: 7,9) or assessed (Mdn: 8; IQR: 8,9) during telemedicine video appointments. The panel also recommended vesicular monoamine transporter-2 (VMAT-2) inhibitors as the first-line treatment if available (Mdn: 9 IQR: 8,9). Other treatment options that were accessible in the region were also suggested.